TY - JOUR
T1 - Neuropsychiatric drug development
T2 - Perspectives on the current landscape, opportunities and potential future directions
AU - Loiodice, Simon
AU - D'Acquisto, Fulvio
AU - Drinkenburg, Pim
AU - Suojanen, Christian
AU - Llorca, Pierre-Michel
AU - Manji, Husseini K
N1 - Copyright © 2024. Published by Elsevier Ltd.
PY - 2024/11/28
Y1 - 2024/11/28
N2 - Mental health represents a major challenge to our societies. One key difficulty associated with neuropsychiatric drug development is the lack of connection between the underlying biology and the disease. Nevertheless, there is growing optimism in this field with recent drug approvals (the first in decades) and renewed interest from pharmaceutical companies and investors. Here we review some of the most promising drug discovery and development endeavors currently deployed by industry. We also present elements illustrating the renewed interest from key stakeholders in neuropsychiatric drug development and provide potential future directions in this field.
AB - Mental health represents a major challenge to our societies. One key difficulty associated with neuropsychiatric drug development is the lack of connection between the underlying biology and the disease. Nevertheless, there is growing optimism in this field with recent drug approvals (the first in decades) and renewed interest from pharmaceutical companies and investors. Here we review some of the most promising drug discovery and development endeavors currently deployed by industry. We also present elements illustrating the renewed interest from key stakeholders in neuropsychiatric drug development and provide potential future directions in this field.
U2 - 10.1016/j.drudis.2024.104255
DO - 10.1016/j.drudis.2024.104255
M3 - Review article
C2 - 39615745
SN - 1359-6446
SP - 104255
JO - Drug discovery today
JF - Drug discovery today
ER -